# Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

> **NCT01641107** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 44 (actual)

## Conditions studied

- Philadelphia Positive
- BCR-ABL Positive
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT01641107
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-04
- **Primary completion:** 2020-04-24
- **Final completion:** 2021-09-30
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641107, "Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01641107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*